Navigation Links
Ranbaxy Voluntarily Recalls Nitrofurantoin Capsules in the U.S.
Date:5/1/2009

PRINCETON, N.J., May 1 /PRNewswire/ -- Ranbaxy Pharmaceuticals Inc. (RPI) announced today that it is conducting a voluntary recall of all lots of Nitrofurantoin (Monohydrate/Macrocrystals) Capsules, USP 100 mg currently on the market in the U.S.

Although certain lots of the product were determined to not be in conformity with the approved laboratory specifications, Ranbaxy decided to recall all the lots, as a matter of abundant caution, given its commitment to the health and safety of patients. Ranbaxy is continuing to look into the cause of such non-conformity.

The recall is being conducted in coordination with the FDA and will be a retail level recall. To the best of Ranbaxy's knowledge, the recalled product is unlikely to produce any serious adverse health effects. However, there is a remote possibility that the non-conforming product may increase the incidence of local non-serious gastrointestinal adverse events such as nausea and vomiting. All patients presently consuming and/or prescribed this formulation should consult their physicians for alternate and appropriate medication/treatment options.

Ranbaxy Pharmaceuticals Inc. (RPI) based in Jacksonville, Florida, is a wholly owned subsidiary of Ranbaxy Laboratories Limited (RLL), India's largest pharmaceutical company. RPI is engaged in the sale and distribution of generic and branded prescription products in the U.S. healthcare system.


'/>"/>
SOURCE Ranbaxy Pharmaceuticals Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Ranbaxy to Consolidate Position in Biopharmaceuticals and Speciality Injectables Including Oncology
2. Astellas and Boehringer Ingelheim Reach Settlement Agreement with Ranbaxy on Flomax Patent Case
3. Ranbaxy Receives Tentative Approval to Manufacture and Market Esomeprazole Magnesium DR Capsules
4. Ranbaxy and AstraZeneca Reach Agreement in Esomeprazole Patent Litigation
5. Ranbaxy Gains Tentative Approval to Manufacture and Market Valganciclovir Hydrochloride Tablets
6. Daiichi Sankyo and Ranbaxy Confirm Deal Is Binding and Final, Allay Market Rumour and Speculation
7. Ranbaxy Launches Omeprazole 40 mg Capsules
8. ETHEX Corporation Voluntarily Recalls Specific Lots of 30 mg. and 60 mg. Morphine Sulfate Extended Release Tablets Due to the Potential for Oversized Tablets
9. China Bio-Immunity Corporation Initiates Voluntary Recalls of Rabies Vaccines
10. Cytochroma initiates Phase I/II clinical trial of CTAP101 Capsules for vitamin D insufficiency in chronic kidney disease
11. Neurocrine Receives Approvable Letter for Indiplon Capsules with Additional Safety and Efficacy Data Required by FDA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/1/2015)... 2015 /PRNewswire/ - BioAmber Inc. (NYSE: BIOA ), ... it has priced an underwritten registered offering of 3,900,000 ... $9.00 per share, and granted the underwriters in the ... additional 585,000 shares of its common stock. The gross ... is expected to close on May 6, 2015, subject ...
(Date:5/1/2015)... A new report by  visiongain ... reach $22.4bn in 2019. That revenue forecast and others ... Prospects 2015-2025 ,  published in March 2015. ... provide forecasts and qualitative analyses of the antithrombotic drugs ... in London, UK . It produces ...
(Date:5/1/2015)... , May 1, 2015 ... "Antibody Production Market by Product (Equipment, Consumables), by Type ... Companies, Diagnostic Labs, Research Institutes) - Analysis & ... report studies the global Antibody Production Market for ... market is expected to reach $2.572 Billion by ...
(Date:4/30/2015)... WARREN, N.J. , April 30, 2015  Roka ... company focused on providing advanced testing solutions for the ... financial results for the first quarter of 2015 on ... markets. Roka Bioscience will also host a ... 7, 2015 to discuss its first quarter financial results. ...
Breaking Biology Technology:BioAmber Inc. Announces Pricing Of $35.1 Million Registered Offering 2BioAmber Inc. Announces Pricing Of $35.1 Million Registered Offering 3Antithrombotic Drugs: World Industry and Market Prospects 2015-2025 2Antithrombotic Drugs: World Industry and Market Prospects 2015-2025 3Antithrombotic Drugs: World Industry and Market Prospects 2015-2025 4Antithrombotic Drugs: World Industry and Market Prospects 2015-2025 5Antibody Production Market worth $2.572 Billion by 2019 2Antibody Production Market worth $2.572 Billion by 2019 3Antibody Production Market worth $2.572 Billion by 2019 4Roka Bioscience to Report First Quarter 2015 Financial Results On May 7, 2015 2
... SANTA CLARA, Calif., March 20 Finesse Solutions, LLC, ... process,applications, is pleased to announce the opening of their ... this new E-Store at,Interphex in Philadelphia. The new E-Store ... ) so that customers can harness the power,of the ...
... March 19 /Xinhua-PRNewswire-FirstCall/ -- 3SBio Inc.,(Nasdaq: ... leading, fully integrated,biotechnology company focused on researching, ... China, announced today,that its board of directors ... The board has authorized 3SBio to purchase ...
... Mass., March 19 AdvanDx announced it ... the Year Award in the,field of rapid ... hospitals depend on AdvanDx,s easy-to-use, molecular-based,PNA FISH(TM) ... hours,instead of days. The rapid PNA FISH ...
Cached Biology Technology:3SBio Inc. Approves Share Repurchase Program 2AdvanDx Receives Frost & Sullivan's Rapid In-Vitro Diagnostic Technology Innovation of the Year Award 2AdvanDx Receives Frost & Sullivan's Rapid In-Vitro Diagnostic Technology Innovation of the Year Award 3AdvanDx Receives Frost & Sullivan's Rapid In-Vitro Diagnostic Technology Innovation of the Year Award 4
(Date:4/2/2015)... , April 2, 2015 According ... 2015 attributed to somewhat higher than 125 MSEK. This ... year-end report 2014 that revenues for Q1 2015 would ... company reported for Q4 2014. The operating result for ... negative. The complete interim report will as previously communicated ...
(Date:3/31/2015)... March 31, 2015   Guidepoint , a leading ... the Post-Surgical Pain Management TRACKER, part of the ... trends in the medical device and therapeutics markets. The ... including treatment volumes, market share, and adoption rates across ... with joint surgery. The Post-Surgical Pain Management ...
(Date:3/24/2015)... , March 24, 2015   NexID Biometrics ... with critical security-authentication needs, today announced the beginning of ... (FFD) solution. The company, based in ... at the three-day Connect:ID Expo, which began here today ... NexID said version 2.0 of its SDK boosts the ...
Breaking Biology News(10 mins):Fingerprint Cards Revises Revenues for Q1 2015 2Guidepoint Launches Post-Surgical Pain Management TRACKER 2Guidepoint Launches Post-Surgical Pain Management TRACKER 3NexID Begins Shipments Of Version 2.0 Fake-Finger-Detection Solution 2
... MA. Wed. March 6, 2013 New work from ... Hospital, Harvard University, MIT, and Yale University expands the ... known as a T helper 17 or Th17 cell ... of immune responses. By figuring out how these cells ...
... JOLLA, CA Scientists at the Salk Institute for ... only allow plants to adapt to various environments, but could ... Published March 6 in Nature , the findings ... throughout the world, their epigenomic makeup is as varied as ...
... All too often, stress turns addiction recovery into ... scientists with insight that might allow them develop a ... Neuron pinpoints the neural basis for stress-related ... advance could accelerate progress toward a medicine that prevents ...
Cached Biology News:Circuitry of cells involved in immunity, autoimmune diseases exposed 2Circuitry of cells involved in immunity, autoimmune diseases exposed 3Circuitry of cells involved in immunity, autoimmune diseases exposed 4Circuitry of cells involved in immunity, autoimmune diseases exposed 5Hidden layer of genome unveils how plants may adapt to environments throughout the world 2Hidden layer of genome unveils how plants may adapt to environments throughout the world 3Study pinpoints, prevents stress-induced drug relapse in rats 2Study pinpoints, prevents stress-induced drug relapse in rats 3
... Cytomics FC 500 Series is ... with the most advanced technologies ... delivers flexible testing, powerful software ... that help researchers optimize their ...
... KineticScan™ Reader is Cellomics‘ latest ... for Cell-based Screening". The KineticScan ... to do both temporal and ... processes, dynamic distribution and activity ...
... Protein/antibody delivery using PULSin may be superior ... example, unlike traditional transfection, with PULSin you ... level and time course of proteins in ... provide more information than traditional RNA interference ...
... an automated instrument with a thin silicon ... using light or fluorescence microscopy. Biaxial strain ... fibroblast cells can be simulated by mechanical ... Y axis of our strain chamber. Strain ...
Biology Products: